Skip to main content
Journal cover image

Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial.

Publication ,  Journal Article
Harrington, J; Udell, JA; Jones, WS; Anker, SD; Bhatt, DL; Petrie, MC; Vedin, O; Sumin, M; Zwiener, I; Hernandez, AF; Butler, J
Published in: Am Heart J
November 2022

BACKGROUND: Patients with acute myocardial infarction (MI) are at risk for developing heart failure (HF) and subsequently are at an increased risk of mortality. Sodium-glucose cotransporter-2 inhibitors have been proven to improve outcomes in patients with HF with reduced ejection fraction, and, in the case of empagliflozin, in HF with preserved ejection fraction even without diabetes, but their efficacy and safety in the post-MI population has not yet been evaluated. METHODS: The EMPACT-MI trial will evaluate the safety and efficacy of empagliflozin compared with placebo in patients hospitalized for MI with or at high risk of new onset HF, in addition to standard care. EMPACT-MI is a streamlined, multinational, randomized, double-blind, placebo-controlled trial randomizing 5,000 participants at approximately 480 centers in 22 countries. Eligible patients presenting with spontaneous MI must have new signs or symptoms of pulmonary congestion requiring treatment or new left ventricular dysfunction (LVEF<45%), and at least 1 additional risk factor for development of future HF. Eligible and consenting patients are randomized to empagliflozin 10mg or placebo daily in addition to standard of care within 14 days of hospital admission for MI. The primary composite end point is time to first hospitalization for HF or all-cause mortality. CONCLUSIONS: EMPACT-MI will inform clinical practice regarding the role of empagliflozin in patients after an MI with high-risk for the development of future HF and mortality.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

November 2022

Volume

253

Start / End Page

86 / 98

Location

United States

Related Subject Headings

  • Ventricular Dysfunction, Left
  • Stroke Volume
  • Sodium-Glucose Transporter 2 Inhibitors
  • Myocardial Infarction
  • Humans
  • Heart Failure
  • Glucosides
  • Double-Blind Method
  • Diabetes Mellitus, Type 2
  • Cardiovascular System & Hematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Harrington, J., Udell, J. A., Jones, W. S., Anker, S. D., Bhatt, D. L., Petrie, M. C., … Butler, J. (2022). Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial. Am Heart J, 253, 86–98. https://doi.org/10.1016/j.ahj.2022.05.010
Harrington, Josephine, Jacob A. Udell, W Schuyler Jones, Stefan D. Anker, Deepak L. Bhatt, Mark C. Petrie, Ola Vedin, et al. “Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial.Am Heart J 253 (November 2022): 86–98. https://doi.org/10.1016/j.ahj.2022.05.010.
Harrington J, Udell JA, Jones WS, Anker SD, Bhatt DL, Petrie MC, et al. Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial. Am Heart J. 2022 Nov;253:86–98.
Harrington, Josephine, et al. “Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial.Am Heart J, vol. 253, Nov. 2022, pp. 86–98. Pubmed, doi:10.1016/j.ahj.2022.05.010.
Harrington J, Udell JA, Jones WS, Anker SD, Bhatt DL, Petrie MC, Vedin O, Sumin M, Zwiener I, Hernandez AF, Butler J. Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial. Am Heart J. 2022 Nov;253:86–98.
Journal cover image

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

November 2022

Volume

253

Start / End Page

86 / 98

Location

United States

Related Subject Headings

  • Ventricular Dysfunction, Left
  • Stroke Volume
  • Sodium-Glucose Transporter 2 Inhibitors
  • Myocardial Infarction
  • Humans
  • Heart Failure
  • Glucosides
  • Double-Blind Method
  • Diabetes Mellitus, Type 2
  • Cardiovascular System & Hematology